4.5 Review

Tackling EGFR signaling with TACE antagonists: a rational target for metalloprotease inhibitors in cancer

Journal

EXPERT OPINION ON THERAPEUTIC TARGETS
Volume 11, Issue 10, Pages 1287-1298

Publisher

INFORMA HEALTHCARE
DOI: 10.1517/14728222.11.10.1287

Keywords

ADAM 17; cancer; EGFR; metalloprotease inhibitor; sheddase

Ask authors/readers for more resources

TNF-alpha converting enzyme (TACE/ADAM17) is a transmembrane metalloprotease that plays a key role in the cleavage and mobilization of receptor ligands that are initially synthesized as membrane-tethered precursors. For many years, attention has focused on the role of TACE-dependent TNF-alpha cleavage in arthritis and, more recently, it has become apparent that TACE also plays an important role in regulating epidermal growth factor receptor activity in several tumor types. This review presents the background to these findings and a rationale for the continued development of TACE inhibitors for the treatment of epidermal growth factor receptor-dependent epithelial tumors.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available